Table 4. Univariate and multivariate analysis of overall survival in patients with metastatic nasopharyngeal carcinoma patients (PSM matched data).
| Variables | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| Sex | 0.057 | ||||
| Female vs. male | 0.56 (0.31–1.02) | ||||
| Age, years | 0.35 | ||||
| >50 vs. ≤50 | 1.23 (0.80–1.89) | ||||
| T classification | |||||
| T1 | 1 | ||||
| T2 | 0.96 (0.44–2.11) | 0.924 | |||
| T3 | 0.86 (0.69–1.87) | 0.672 | |||
| T4 | 0.69 (0.66–1.85) | 0.315 | |||
| N classification | |||||
| N1 | 1 | ||||
| N2 | 1.19 (0.49–2.89) | 0.704 | |||
| N3 | 1.79 (0.77–4.16) | 0.177 | |||
| Histology | |||||
| I | 1 | ||||
| II | 0.49 (0.25–1.01) | 0.231 | |||
| III | 4.80 (0.65–35.73) | 0.125 | |||
| ECOG | 0.93 | ||||
| 1 vs. 0 | 0.98 (0.57–1.68) | ||||
| IMRT | 0.013 | 0.032 | |||
| Yes vs. no | 0.55 (0.35–0.88) | 0.60 (0.37–0.96) | |||
| SII | 0.002 | 0.004 | |||
| ≥930 vs. <930 | 1.96 (1.29–2.94) | 1.86 (1.22–2.83) | |||
ECOG, Eastern Cooperative Oncology Group performance; IMRT, intensity modulated radiotherapy; HR, hazard ratio; CI, confidence interval. SII, systemic immune-inflammation index.